Drug company merger should benefit researchBMJ 1998; 316 doi: https://doi.org/10.1136/bmj.316.7130.493c (Published 14 February 1998) Cite this as: BMJ 1998;316:493
- George Labreque
The likely impact of the proposed merger between GlaxoWellcome and SmithKline Beecham is still unclear, though industry and government officials generally believe that in the long term it will boost the British science research base as well as the health of the two companies.
Britain's biggest pharmaceutical manufacturers announced on 30 January that they were discussing a merger after talks between SmithKline Beecham and American Home Products broke down. Talks could last several more weeks, company officials said. The move would be the biggest corporate merger ever, creating by far the largest pharmaceutical company, with more than $27bn (£17bn) in sales and a global market share of about 8%.
For Britain, ever concerned that it may lose its world class science research base, a new company comprising GlaxoWellcome and SmithKline Beecham would be a key …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial